Merck Announces FDA Acceptance of New Drug Application for an Investigational Tablet Formulation of the Antifungal NOXAFIL® (posaconazole)

Dateline City: 

WHITEHOUSE STATION N.J.

WHITEHOUSE STATION N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada,
today announced that its New Drug Application for an investigational,
tablet formulation of the company's antifungal agent, NOXAFIL®
(posaconazole), has been accepted for review by the U.S. Food and Drug
Administration (FDA).

Language: 

English

Contact HTML: 

MerckMedia:Pam Eisele, [phone]Robert Consalvo, [phone]orInvestor:Carol Ferguson, [phone]Justin Holko, [phone]

Ticker Slug: 

Ticker: MRK Exchange: NYSE

read more

Source: Merck.com - Product News - April 10, 2013 Category: Drugs & Pharmacology Authors: hq_site_admin Tags: Prescription Medicine News Corporate News Source Type: news